Clinical Leadership MSB operates the only CLIA lab offering both CTC enumeration and phenotyping with CellSearch along with comprehensive cfDNA/RNA genomic profiling, positioning it as a pioneer in liquid biopsy services for cancer patient monitoring and biomarker discovery.

Integrated Genomics MenariniSearch leverages next-generation sequencing powered by AI to detect a broad range of genetic alterations across most cancer types, presenting opportunities to upsell advanced molecular profiling to institutions seeking actionable targets for personalized therapy.

Accredited Reliability CLIA and CAP accreditation with pathologist review enhances credibility for hospital labs and oncology clinics evaluating external testing partners, making MSB a trusted option for diagnostic integration and second opinions.

Strategic Partnerships As a wholly owned subsidiary of the global Menarini Group, MSB can pursue collaborations spanning diagnostics development, biopharma clinical trials, and payer-ready genomic testing, expanding access through a multinational network.

Growth Signals With a revenue range of 50–100 million and a lean employee base, there is potential to scale via technology integrations, expanded assay menus, and targeted outreach to mid-market hospitals and cancer centers seeking liquid biopsy capabilities.